Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference?

Because adolescent and young adult (AYA) patients with cancer have experienced variable improvement in survival over the past two decades, enhancing the quality and timeliness of cancer care in this population has emerged as a priority area. To identify current trends in AYA care, we examined patter...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of clinical oncology Ročník 29; číslo 30; s. 4045
Hlavní autori: Parsons, Helen M, Harlan, Linda C, Seibel, Nita L, Stevens, Jennifer L, Keegan, Theresa H M
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 20.10.2011
Predmet:
ISSN:1527-7755, 1527-7755
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Because adolescent and young adult (AYA) patients with cancer have experienced variable improvement in survival over the past two decades, enhancing the quality and timeliness of cancer care in this population has emerged as a priority area. To identify current trends in AYA care, we examined patterns of clinical trial participation, time to treatment, and provider characteristics in a population-based sample of AYA patients with cancer. Using the National Cancer Institute Patterns of Care Study, we used multivariate logistic regression to evaluate demographic and provider characteristics associated with clinical trial enrollment and time to treatment among 1,358 AYA patients with cancer (age 15 to 39 years) identified through the Surveillance, Epidemiology, and End Results Program. In our study, 14% of patients age 15 to 39 years had enrolled onto a clinical trial; participation varied by type of cancer, with the highest participation in those diagnosed with acute lymphoblastic leukemia (37%) and sarcoma (32%). Multivariate analyses demonstrated that uninsured, older patients and those treated by nonpediatric oncologists were less likely to enroll onto clinical trials. Median time from pathologic confirmation to first treatment was 3 days, but this varied by race/ethnicity and cancer site. In multivariate analyses, advanced cancer stage and outpatient treatment alone were associated with longer time from pathologic confirmation to treatment. Our study identified factors associated with low clinical trial participation in AYA patients with cancer. These findings support the continued need to improve access to clinical trials and innovative treatments for this population, which may ultimately translate into improved survival.
AbstractList Because adolescent and young adult (AYA) patients with cancer have experienced variable improvement in survival over the past two decades, enhancing the quality and timeliness of cancer care in this population has emerged as a priority area. To identify current trends in AYA care, we examined patterns of clinical trial participation, time to treatment, and provider characteristics in a population-based sample of AYA patients with cancer. Using the National Cancer Institute Patterns of Care Study, we used multivariate logistic regression to evaluate demographic and provider characteristics associated with clinical trial enrollment and time to treatment among 1,358 AYA patients with cancer (age 15 to 39 years) identified through the Surveillance, Epidemiology, and End Results Program. In our study, 14% of patients age 15 to 39 years had enrolled onto a clinical trial; participation varied by type of cancer, with the highest participation in those diagnosed with acute lymphoblastic leukemia (37%) and sarcoma (32%). Multivariate analyses demonstrated that uninsured, older patients and those treated by nonpediatric oncologists were less likely to enroll onto clinical trials. Median time from pathologic confirmation to first treatment was 3 days, but this varied by race/ethnicity and cancer site. In multivariate analyses, advanced cancer stage and outpatient treatment alone were associated with longer time from pathologic confirmation to treatment. Our study identified factors associated with low clinical trial participation in AYA patients with cancer. These findings support the continued need to improve access to clinical trials and innovative treatments for this population, which may ultimately translate into improved survival.
Because adolescent and young adult (AYA) patients with cancer have experienced variable improvement in survival over the past two decades, enhancing the quality and timeliness of cancer care in this population has emerged as a priority area. To identify current trends in AYA care, we examined patterns of clinical trial participation, time to treatment, and provider characteristics in a population-based sample of AYA patients with cancer.PURPOSEBecause adolescent and young adult (AYA) patients with cancer have experienced variable improvement in survival over the past two decades, enhancing the quality and timeliness of cancer care in this population has emerged as a priority area. To identify current trends in AYA care, we examined patterns of clinical trial participation, time to treatment, and provider characteristics in a population-based sample of AYA patients with cancer.Using the National Cancer Institute Patterns of Care Study, we used multivariate logistic regression to evaluate demographic and provider characteristics associated with clinical trial enrollment and time to treatment among 1,358 AYA patients with cancer (age 15 to 39 years) identified through the Surveillance, Epidemiology, and End Results Program.METHODSUsing the National Cancer Institute Patterns of Care Study, we used multivariate logistic regression to evaluate demographic and provider characteristics associated with clinical trial enrollment and time to treatment among 1,358 AYA patients with cancer (age 15 to 39 years) identified through the Surveillance, Epidemiology, and End Results Program.In our study, 14% of patients age 15 to 39 years had enrolled onto a clinical trial; participation varied by type of cancer, with the highest participation in those diagnosed with acute lymphoblastic leukemia (37%) and sarcoma (32%). Multivariate analyses demonstrated that uninsured, older patients and those treated by nonpediatric oncologists were less likely to enroll onto clinical trials. Median time from pathologic confirmation to first treatment was 3 days, but this varied by race/ethnicity and cancer site. In multivariate analyses, advanced cancer stage and outpatient treatment alone were associated with longer time from pathologic confirmation to treatment.RESULTSIn our study, 14% of patients age 15 to 39 years had enrolled onto a clinical trial; participation varied by type of cancer, with the highest participation in those diagnosed with acute lymphoblastic leukemia (37%) and sarcoma (32%). Multivariate analyses demonstrated that uninsured, older patients and those treated by nonpediatric oncologists were less likely to enroll onto clinical trials. Median time from pathologic confirmation to first treatment was 3 days, but this varied by race/ethnicity and cancer site. In multivariate analyses, advanced cancer stage and outpatient treatment alone were associated with longer time from pathologic confirmation to treatment.Our study identified factors associated with low clinical trial participation in AYA patients with cancer. These findings support the continued need to improve access to clinical trials and innovative treatments for this population, which may ultimately translate into improved survival.CONCLUSIONOur study identified factors associated with low clinical trial participation in AYA patients with cancer. These findings support the continued need to improve access to clinical trials and innovative treatments for this population, which may ultimately translate into improved survival.
Author Harlan, Linda C
Stevens, Jennifer L
Parsons, Helen M
Seibel, Nita L
Keegan, Theresa H M
Author_xml – sequence: 1
  givenname: Helen M
  surname: Parsons
  fullname: Parsons, Helen M
  email: helen.parsons@nih.gov
  organization: Applied Research Program, National Cancer Institute, Bethesda, MD 20892-7344, USA. helen.parsons@nih.gov
– sequence: 2
  givenname: Linda C
  surname: Harlan
  fullname: Harlan, Linda C
– sequence: 3
  givenname: Nita L
  surname: Seibel
  fullname: Seibel, Nita L
– sequence: 4
  givenname: Jennifer L
  surname: Stevens
  fullname: Stevens, Jennifer L
– sequence: 5
  givenname: Theresa H M
  surname: Keegan
  fullname: Keegan, Theresa H M
BackLink https://www.ncbi.nlm.nih.gov/pubmed/21931022$$D View this record in MEDLINE/PubMed
BookMark eNpNkE1LAzEQhoNUbP24e5LcPLUm2U0360Wk-IngRc9lNpmt0d2kJlnEf-LPNdUKXmaG530YmNknI-cdEnLM2YwLxs7uF48zwTifFfOZqGW5QyZcimpaVVKO_s1jsh_jK2O8VIXcI2PB64IzISbka9FZZzV0NAWb6xpCstquIVnvKDhDk-2RJp9zhNSjSxR671YUjO8w6gzij_fphx86dBl82PRCNTiN4Zwaj1lZIYVEjYWV89FG6gO1Lg5hI9Ee3nKc07bFgJlcHJLdFrqIR9t-QJ6vr54Wt9OHx5u7xeXDVJeySlOpinZeK1A4Nw1CWUKjdFm0TJmiamsjJeNaKGYaoTQXxsAmEAWapmmVkuKAnP7uXQf_PmBMy97mq7oOHPohLmvG5kIqvjFPtubQ9GiW62B7CJ_Lv2eKb6X9e4o
CitedBy_id crossref_primary_10_1001_jamanetworkopen_2023_28153
crossref_primary_10_1111_ecc_12476
crossref_primary_10_1634_theoncologist_2014_0265
crossref_primary_10_1016_j_bulcan_2020_09_004
crossref_primary_10_1111_bjh_12556
crossref_primary_10_3322_caac_21585
crossref_primary_10_1542_peds_2014_0122C
crossref_primary_10_1097_MPH_0000000000003066
crossref_primary_10_1542_peds_2014_0122B
crossref_primary_10_1542_peds_2014_0122E
crossref_primary_10_4103_ijmpo_ijmpo_185_20
crossref_primary_10_1053_j_seminoncol_2018_04_002
crossref_primary_10_1542_peds_2014_0122G
crossref_primary_10_1542_peds_2014_0122I
crossref_primary_10_1080_00981389_2019_1640338
crossref_primary_10_1002_pbc_27033
crossref_primary_10_3171_2015_2_JNS142960
crossref_primary_10_1089_jayao_2015_0041
crossref_primary_10_1097_MS9_0000000000001398
crossref_primary_10_3322_caac_21731
crossref_primary_10_1002_cncr_29193
crossref_primary_10_1089_jayao_2020_0041
crossref_primary_10_1371_journal_pone_0230824
crossref_primary_10_1177_107327481602300414
crossref_primary_10_1002_cncr_29870
crossref_primary_10_1002_pon_3730
crossref_primary_10_1002_cam4_4292
crossref_primary_10_1002_cncr_33855
crossref_primary_10_1002_cncr_34702
crossref_primary_10_1186_s12909_024_06164_w
crossref_primary_10_1007_s11912_022_01276_2
crossref_primary_10_1089_jayao_2019_0107
crossref_primary_10_1089_jayao_2021_0187
crossref_primary_10_1200_JCO_2012_47_3173
crossref_primary_10_1002_pbc_27426
crossref_primary_10_3322_caac_21565
crossref_primary_10_3390_ijms23073540
crossref_primary_10_1001_jama_2019_15040
crossref_primary_10_1007_s40124_015_0075_y
crossref_primary_10_1111_bjh_15640
crossref_primary_10_1001_jamanetworkopen_2021_16248
crossref_primary_10_1002_cncr_29982
crossref_primary_10_1002_cncr_27685
crossref_primary_10_1093_oncolo_oyaf180
crossref_primary_10_1089_jayao_2024_0095
crossref_primary_10_1097_MOP_0000000000001200
crossref_primary_10_2196_17078
crossref_primary_10_1002_cncr_29869
crossref_primary_10_1200_JCO_2011_39_6333
crossref_primary_10_1159_000363434
crossref_primary_10_1038_nrclinonc_2015_92
crossref_primary_10_1089_jayao_2021_0110
crossref_primary_10_3390_children6110117
crossref_primary_10_1089_jayao_2013_0030
crossref_primary_10_1007_s11764_013_0332_4
crossref_primary_10_1007_s11764_021_01161_0
crossref_primary_10_1089_jayao_2021_0008
crossref_primary_10_1080_10428194_2025_2499607
crossref_primary_10_1007_s00520_016_3558_7
crossref_primary_10_1016_j_canep_2016_09_013
crossref_primary_10_1016_j_clml_2014_12_006
crossref_primary_10_1177_10732748251364041
crossref_primary_10_4251_wjgo_v12_i12_1394
crossref_primary_10_1136_bmjopen_2017_017052
crossref_primary_10_1371_journal_pone_0154985
crossref_primary_10_1002_pbc_27486
crossref_primary_10_2196_37054
crossref_primary_10_1016_S1470_2045_17_30100_6
crossref_primary_10_1002_pbc_24231
crossref_primary_10_1053_j_seminoncol_2015_07_012
crossref_primary_10_2217_cpr_12_30
crossref_primary_10_1002_pbc_27074
crossref_primary_10_1002_cncr_31127
crossref_primary_10_1089_jayao_2021_0014
crossref_primary_10_1245_s10434_012_2621_y
crossref_primary_10_1002_pbc_27235
crossref_primary_10_1007_s10880_021_09764_6
crossref_primary_10_1089_jayao_2019_0139
crossref_primary_10_1002_cam4_1307
crossref_primary_10_1007_s10147_021_02064_x
crossref_primary_10_1016_j_clml_2020_06_010
crossref_primary_10_1200_OP_24_01075
crossref_primary_10_1097_COC_0000000000000327
crossref_primary_10_1002_pbc_30592
crossref_primary_10_1016_j_soncn_2015_05_006
crossref_primary_10_3390_cancers14102451
crossref_primary_10_1016_j_soncn_2015_05_001
crossref_primary_10_1089_jayao_2021_0026
crossref_primary_10_1093_nop_npab001
crossref_primary_10_1007_s40471_022_00286_9
crossref_primary_10_1186_s12884_021_03854_x
crossref_primary_10_1002_pbc_28315
crossref_primary_10_1002_pbc_25843
crossref_primary_10_1007_s12529_023_10162_5
crossref_primary_10_1080_10428194_2019_1574002
crossref_primary_10_1002_pbc_26638
crossref_primary_10_1007_s11764_012_0219_9
crossref_primary_10_1038_s41598_022_07703_5
crossref_primary_10_1016_j_ejim_2016_06_026
crossref_primary_10_1200_EDBK_323523
crossref_primary_10_1002_ijc_28231
crossref_primary_10_1089_jayao_2014_0041
crossref_primary_10_1097_MD_0000000000027560
crossref_primary_10_1200_JCO_2016_70_3249
crossref_primary_10_1002_cncr_32038
crossref_primary_10_1089_jayao_2019_0078
crossref_primary_10_1002_cncr_29669
crossref_primary_10_1182_bloodadvances_2017014944
crossref_primary_10_2196_48761
crossref_primary_10_1002_pbc_29479
crossref_primary_10_1093_oncolo_oyac030
crossref_primary_10_1371_journal_pone_0280638
crossref_primary_10_1002_cncr_32675
crossref_primary_10_1089_jayao_2022_0006
crossref_primary_10_3390_cancers13112675
crossref_primary_10_1001_jamanetworkopen_2021_21888
crossref_primary_10_1089_jayao_2018_0140
crossref_primary_10_3322_caac_21235
crossref_primary_10_1002_cncr_33190
crossref_primary_10_1002_cncr_31727
crossref_primary_10_1002_cam4_2891
crossref_primary_10_1002_cncr_28685
crossref_primary_10_1089_jayao_2012_0024
crossref_primary_10_1007_s00520_013_1809_4
crossref_primary_10_1097_j_pain_0000000000002893
crossref_primary_10_1089_jayao_2017_0060
crossref_primary_10_1089_jayao_2012_0029
crossref_primary_10_3322_caac_21349
crossref_primary_10_3109_10428194_2015_1083562
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1200/JCO.2011.36.2954
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1527-7755
ExternalDocumentID 21931022
Genre Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: N01 PC035139
– fundername: NCI NIH HHS
  grantid: N01-PC-35135
– fundername: NCI NIH HHS
  grantid: N01 PC054402
– fundername: NCI NIH HHS
  grantid: N01-PC-54403
– fundername: NCI NIH HHS
  grantid: N01 PC035138
– fundername: NCI NIH HHS
  grantid: N01 PC035145
– fundername: NCI NIH HHS
  grantid: N01 PC054405
– fundername: NCI NIH HHS
  grantid: N01 PC035141
– fundername: NCI NIH HHS
  grantid: N01-PC-35143
– fundername: NCI NIH HHS
  grantid: N01 PC035135
GroupedDBID ---
.55
0R~
18M
2WC
34G
39C
3O-
4.4
53G
5GY
5RE
8F7
AARDX
AAWTL
AAYEP
ABBLC
ABJNI
ABOCM
ACGFO
ACGFS
ACGUR
ADBBV
AEGXH
AENEX
AFFNX
AI.
AIAGR
ALMA_UNASSIGNED_HOLDINGS
BAWUL
C45
CGR
CS3
CUY
CVF
DIK
EBS
ECM
EIF
EJD
F5P
F9R
FBNNL
FD8
GX1
H13
HZ~
IH2
KQ8
L7B
LSO
MJL
N9A
NPM
O9-
OK1
OVD
OWW
P2P
QTD
R1G
RHI
RLZ
RUC
SJN
TEORI
TR2
TWZ
UDS
VH1
VVN
WH7
X7M
YFH
YQY
7X8
ID FETCH-LOGICAL-c457t-583f698a8e6dbea44ab8c43f08d37f9d5501c280db28c12dda8d3723edbbf8852
IEDL.DBID 7X8
ISICitedReferencesCount 159
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000296551700021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1527-7755
IngestDate Fri Sep 05 13:37:58 EDT 2025
Mon Jul 21 06:03:06 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 30
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c457t-583f698a8e6dbea44ab8c43f08d37f9d5501c280db28c12dda8d3723edbbf8852
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2011.36.2954?role=tab
PMID 21931022
PQID 900625815
PQPubID 23479
ParticipantIDs proquest_miscellaneous_900625815
pubmed_primary_21931022
PublicationCentury 2000
PublicationDate 2011-10-20
PublicationDateYYYYMMDD 2011-10-20
PublicationDate_xml – month: 10
  year: 2011
  text: 2011-10-20
  day: 20
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of clinical oncology
PublicationTitleAlternate J Clin Oncol
PublicationYear 2011
SSID ssj0014835
Score 2.4475062
Snippet Because adolescent and young adult (AYA) patients with cancer have experienced variable improvement in survival over the past two decades, enhancing the...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 4045
SubjectTerms Adolescent
Adult
Age Factors
Clinical Trials as Topic - statistics & numerical data
Female
Humans
Logistic Models
Male
Neoplasms - epidemiology
Neoplasms - therapy
Patient Selection
Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology
Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy
Research Subjects
Sarcoma - epidemiology
Sarcoma - therapy
SEER Program
United States - epidemiology
Young Adult
Title Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference?
URI https://www.ncbi.nlm.nih.gov/pubmed/21931022
https://www.proquest.com/docview/900625815
Volume 29
WOSCitedRecordID wos000296551700021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JTsMwELXYhLiw74vmgDgRSO0sDheEEBVCaukBpN4qb0EVkJSmIPVP-Fw8jku5IA5ccrETRfJkMuP3_B4hxwi1qVCyIGRxYhsUEQaoQhaYTMqEaikFzZ3ZRNpu824363huTuVplZOc6BK1LhXukZ9neNov5o34cvAWoGkUgqveQWOWzDNbySCjK-1OQYSIO39NNG61RWQce5TSxsX53fV9Ld_JkjNEun6vL91_prnyzzdcJcu-wISrOiLWyIwp1sliy0Po6-SkU4tVj0_hYXr2qjqFE-hMZazHG-TTS4a-gHP2gIH4wcAGUWhAX3oYlfBNVgdnXQQ_VKLcvDFmFHBKHxXgxi8ojLXhBejS2ClPBsQIdE3661dQDgEp8mj5YeBVPNthmBi5KHO5SR6bNw_Xt4H3cQhUFKcjPNiVJxkX3CRaGhFFQnIVsTzkmqV5pm2T1FCUh1pSrhpUa4EDlBkbKjnnMd0ic0VZmB0CUlGlmG25ZKoiJSMZ2yenmmlbCUqa8l0Ck7Xp2e8EwQ9RmPK96n2vzi7Zrte3N6j1PHo2aTNsfPf-vnmfLFFPAqThAZnPbY4wh2RBfYz61fDIxZ-9tjutL1gI6A0
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+trial+participation+and+time+to+treatment+among+adolescents+and+young+adults+with+cancer%3A+does+age+at+diagnosis+or+insurance+make+a+difference%3F&rft.jtitle=Journal+of+clinical+oncology&rft.au=Parsons%2C+Helen+M&rft.au=Harlan%2C+Linda+C&rft.au=Seibel%2C+Nita+L&rft.au=Stevens%2C+Jennifer+L&rft.date=2011-10-20&rft.issn=1527-7755&rft.eissn=1527-7755&rft.volume=29&rft.issue=30&rft.spage=4045&rft_id=info:doi/10.1200%2FJCO.2011.36.2954&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-7755&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-7755&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-7755&client=summon